Medivir is developing tumor-directed nucleotide oral prodrugs to treat cancers with highly unmet medical needs. The company’s lead drug candidate, MIV-818, is a liver cancer targeted prodrug ...

Its effect is based on the breaking of the disulfide bridges of mucus glycoproteins ... With these two blocked thiol groups, erdosteine is an inactive prodrug. Erdosteine is stable only in ...